Windtree Therapeutics

About:

Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.

Website: http://www.windtreetx.com/

Twitter/X: windtreetx

Top Investors: Deerfield, National Institutes of Health, VMS Asset Management

Description:

Windtree Therapeutics (formerly Discovery Laboratories) is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant — and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.